| Nov 4 |
Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy Right Now?
|
| Nov 1 |
Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
|
| Nov 1 |
Bristol Myers posts long-term Phase 3 data for schizophrenia drug Cobenfy
|
| Nov 1 |
Company News for Nov 1, 2024
|
| Nov 1 |
Bristol-Myers Squibb Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Nov 1 |
Bristol-Myers Squibb Co (BMY) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic ...
|
| Nov 1 |
Q3 2024 Bristol-Myers Squibb Co Earnings Call
|
| Nov 1 |
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
|
| Oct 31 |
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
|
| Oct 31 |
A promising schizophrenia drug showed mixed results. What does that mean for patients?
|
